Exploring DOI. To explore a different substance…

Names:
DOI · 4-Iodo-2,5-dimethoxyamphetamine · 2,5-Dimethoxy-4-iodoamphetamine
IUPAC name:
1-(4-Iodo-2,5-dimethoxyphenyl)propan-2-amine
ID: 67 · Formula: C11H16INO2 · Molecular weight: 321.155
InChI: InChI=1S/C11H16INO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3

Silva, ME. Theoretical study of the interaction of agonists with the 5-HT2A receptor. Ph. D. Thesis, Universität Regensburg, Regensburg, Germany, 26 Aug 2008. 5.9 MB.

Braden, MR; Parrish, JC; Naylor, JC; Nichols, DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339^(6.51) and Phe340^(6.52) with superpotent N-benzyl phenethylamine agonists. Mol. Pharmacol., 1 Jan 2006, 70 (6), 1956–1964. 361 kB. http://dx.doi.org/10.1124/mol.106.028720

Moya, PR; Berg, KA; Gutiérrez-Hernandez, MA; Sáez-Briones, P; Reyes-Parada, M; Cassels, BK; Clarke, WP. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J. Pharmacol. Exp. Ther., 1 Jun 2007, 321 (3), 1054–1061. 188 kB. http://dx.doi.org/10.1124/jpet.106.117507

Parrish, JC; Braden, MR; Gundy, E; Nichols, DE. Differential phospholipase C activation by phenylalkylamine serotonin 5-HT2A receptor agonists. J. Neurochem., 1 Dec 2005, 95 (6), 1575–1584. 301 kB. http://dx.doi.org/10.1111/j.1471-4159.2005.03477.x

Acuña-Castillo, C; Villalobos, C; Moya, PR; Sáez, P; Cassels, BK; Huidobro-Toro, JP. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT2A and 5-HT2C receptors. Br. J. Pharmacol., 1 Jun 2002, 136 (4), 510–519. 232 kB. http://dx.doi.org/10.1038/sj.bjp.0704747

Sargent, T; Shulgin, AT; Mathis, CA. Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography. J. Med. Chem., 1 Jan 1984, 27 (8), 1071–1077. 1.9 MB. http://dx.doi.org/10.1021/jm00374a023 Rhodium.

Braun, U; Shulgin, AT; Braun, G; Sargent, T. Synthesis and body distribution of several iodine-131-labeled central nervous system active drugs. J. Med. Chem., 1 Jan 1977, 20 (12), 1543–1546. 1.1 MB. http://dx.doi.org/10.1021/jm00222a001

Seggel, MR; Yousif, MY; Lyon, RA; Titeler, M; Roth, BL; Suba, EA; Glennon, RA. A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors. J. Med. Chem., 1 Mar 1990, 33 (3), 1032–1036. 807 kB. http://dx.doi.org/10.1021/jm00165a023

Glennon, RA; McKenney, JD; Lyon, RA; Titeler, M. 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogs. J. Med. Chem., 1 Feb 1986, 29 (2), 194–199. 919 kB. http://dx.doi.org/10.1021/jm00152a005

Glennon, RA; Raghupathi, R; Bartyzel, P; Teitler, M; Leonhardt, S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem., 1 Feb 1992, 35 (4), 734–740. 1.1 MB. http://dx.doi.org/10.1021/jm00082a014

Perez-Aguilar, JM; Shan, J; LeVine, MV; Khelashvili, G; Weinstein, H. A Functional Selectivity Mechanism at the Serotonin-2A GPCR Involves Ligand-Dependent Conformations of Intracellular Loop 2. J. Am. Chem. Soc., 12 Nov 2014, 136 (45), 16044–16054. 4.2 MB. http://dx.doi.org/10.1021/ja508394x

Braden, MR; Nichols, DE. Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol. Pharmacol., 1 Jan 2007, 72 (5), 1200–1209. 487 kB. http://dx.doi.org/10.1124/mol.107.039255

Coutts, RT; Malicky, JL. The synthesis of some analogs of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM). Can. J. Chem., 1 Jan 1973, 51 (9), 1402–1409. 746 kB. http://dx.doi.org/10.1139/v73-210

Ray, TS. Psychedelics and the human receptorome. PLOS ONE, 2 Feb 2010, 5 (2), e9019. 791 kB. http://dx.doi.org/10.1371/journal.pone.0009019

Ewald, AH. The 2,5-Dimethoxyamphetamines—A new class of designer drugs. Ph. D. Thesis, Universität des Saarlandes, Saarbrücken, Germany, 1 Jan 2008. 195 kB.

Cozzi, NV. Pharmacological studies of some psychoactive phenylalkylamines: entactogens, hallucinogens, and anorectics. Ph. D. Thesis, University Of Wisconsin-Madison, 1 Jan 1994. 10.6 MB.

Schindler, EAD. Behavioral and biochemical distinctions in the pharmacology of two common hallucinogens. Ph. D. Thesis, Drexel University, Philadelphia, PA, USA, 1 Apr 2010. 5.9 MB.

Ang, RLL. Molecular basis of the action of hallucinogens. Ph. D. Thesis, New York University, New York, NY, USA, 2010. 2.4 MB.

Braden, MR. Towards a biophysical understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2007. 8.4 MB.

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2006. 5.5 MB.

Sargent, T; Budinger, TF; Braun, G; Shulgin, AT; Braun, U. An iodinated catecholamine congener for brain imaging and metabolic studies. J. Nucl. Med., 1 Jan 1978, 19 (1), 71–76. 922 kB.

Fenderson5555. DOC, DOB, DOI and DOET: Strategic considerations. 7 Sep 2013. 9.5 MB.

Sargent, T; Braun, G; Braun, U; Budinger, TF; Shulgin, AT. Brain and retina uptake of a radio-iodine labeled psychotomimetic in dog and monkey. Commun. Psychopharmacol., 1 Jan 1978, 2 (1), 1–10. 2.0 MB.

Pigott, A; Frescas, SP; McCorvy, JD; Huang, X; Roth, BL; Nichols, DE. trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT2 receptor family. Beilstein J. Org. Chem., 8 Oct 2012, 8, 1705–1709. 298 kB. http://dx.doi.org/10.3762/bjoc.8.194

Glennon, RA; Seggel, MR. Interaction of phenylisopropylamines with central 5-HT2 receptors. Analysis by quantitative structure-activity relationships. In Probing Bioactive Mechanisms; ACS Symposium Series; Magee, PS; Henry, DR; Block, JH, Eds., American Chemical Society, Washington, DC, 14 Nov 1989; Vol. 413, pp 264–280. 4.4 MB. http://dx.doi.org/10.1021/bk-1989-0413.ch018

Schindler, EA; Dave, KD; Smolock, EM; Aloyo, VJ; Harvey, JA. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Pharmacol. Biochem. Behav., 1 Mar 2012, 101 (1), 69–76. 722 kB. http://dx.doi.org/10.1016/j.pbb.2011.12.002

Fox, MA; French, HT; LaPorte, JL; Blackler, AR; Murphy, DL. The serotonin 5-HT2A receptor agonist TCB-2: A behavioral and neurophysiological analysis. Psychopharmacology, 1 Sep 2010, 212 (1), 13–23. 240 kB. http://dx.doi.org/10.1007/s00213-009-1694-1

Marona-Lewicka, D; Kurrasch-Orbaugh, DM; Selken, JR; Cumbay, MG; Lisnicchia, JG; Nichols, DE. Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioural effects overlap its other properties in rats. Psychopharmacology, 1 Oct 2002, 164 (1), 93–107. 293 kB. http://dx.doi.org/10.1007/s00213-002-1141-z

Nelson, DL; Lucaites, VL; Wainscott, DB; Glennon, RA. Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors. N-S. Arch. Pharmacol., 1 Jan 1999, 359 (1), 1–6. 66 kB. http://dx.doi.org/10.1007/PL00005315

Shulgin, AT. Psychotomimetic drugs: structure-activity relationships. In Handbook of Psychopharmacology: Stimulants; Iversen, LL; Iversen, SD; Snyder, SH, Eds., Plenum Press, New York, 1978; Vol. 11, pp 243–333. 2.6 MB. http://dx.doi.org/10.1007/978-1-4757-0510-2_6 Rhodium.

Halberstadt, AL. Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens. In Current Topics in Behavioral Neurosciences; , 2016; pp 1–29. 826 kB. http://dx.doi.org/10.1007/7854_2016_64

Dawson, BA; Black, DB; Sy, W; Graham, K. 13C NMR of some iodinated methoxy-amphetamines. Magn. Reson. Chem., 1 Sep 1994, 32 (9), 557–558. 171 kB. http://dx.doi.org/10.1002/mrc.1260320913

Sargent, T; Shulgin, AT; Mathis, CA. New iodinated amphetamines by rapid synthesis for use as brain blood flow indicators. J. Labelled Compd. Radiopharm., 1 Jan 1984, 19 (11–12), 1307–1308. 84 kB. http://dx.doi.org/10.1002/jlcr.2580191102

Braun, G; Shulgin, AT; Sargent, T. Synthesis of 123I-labelled 4-iodo-2,5-dimethoxyphenylisopropylamine. J. Labelled Compd. Radiopharm., 1 Jan 1978, 14 (5), 767–773. 291 kB. http://dx.doi.org/10.1002/jlcr.2580140515 Rhodium.

Trachsel, D. Fluorine in psychedelic phenethylamines. Drug Test. Analysis, 1 Jul 2012, 4 (7-8), 577-590. 1.0 MB. http://dx.doi.org/10.1002/dta.413

Blaazer, AR; Smid, P; Kruse, CG. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT2A receptors. ChemMedChem, 15 Sep 2008, 3 (9), 1299–1309. 461 kB. http://dx.doi.org/10.1002/cmdc.200800133

Schulze-Alexandru, M; Kovar, K; Vedani, A. Quasi-atomistic receptor surrogates for the 5-HT2A receptor: A 3D-QSAR study on hallucinogenic substances. Quant. Struct.-Act. Relat., 1 Dec 1999, 18 (6), 548–560. 312 kB. http://dx.doi.org/10.1002/(SICI)1521-3838(199912)18:6<548::AID-QSAR548>3.0.CO;2-B

Silva, ME; Heim, R; Strasser, A; Elz, S; Dove, S. Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor. J. Comput. Aided Mol. Des., 1 Jan 2011, 25 (1), 51–66. 834 kB. http://dx.doi.org/10.1007/s10822-010-9400-2

Kanai, K; Takekawa, K; Kumamoto, T; Ishikawa, T; Ohmori, T. Simultaneous analysis of six phenethylamine-type designer drugs by TLC, LC-MS, and GC-MS. Forensic Toxicol., 1 Nov 2008, 26 (2), 6–12. 406 kB. http://dx.doi.org/10.1007/s11419-008-0041-2

Shannon, M; Battaglia, G; Glennon, RA; Titeler, M. 5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA). Eur. J. Pharmacol., 15 Jun 1984, 102 (1), 23–29. 461 kB. http://dx.doi.org/10.1016/0014-2999(84)90333-9

Halberstadt, AL; Geyer, MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 1 Sep 2011, 61 (3) 364–381. 817 kB. http://dx.doi.org/10.1016/j.neuropharm.2011.01.017

Moreno, JL; Holloway, T; Albizu, L; Sealfon, SC; González-Maeso, J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci. Lett., 15 Apr 2011, 493 (3), 76–79. 196 kB. http://dx.doi.org/10.1016/j.neulet.2011.01.046

Nakanishi, K; Miki, A; Zaitsu, K; Kamata, H; Shima, N; Kamata, T; Katagi, M; Tatsuno, M; Tsuchihashi, H; Suzuki, K. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement. Forensic Sci. Int., 10 Apr 2012, 217 (1–3), 174–181. 397 kB. http://dx.doi.org/10.1016/j.forsciint.2011.11.003

Parker, MA; Kurrasch, DM; Nichols, DE. The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg. Med. Chem., 1 Jan 2008, 16 (8), 4661–4669. 296 kB. http://dx.doi.org/10.1016/j.bmc.2008.02.033

Thakur, M; Thakur, A; Khadikar, PV. QSAR studies on psychotomimetic phenylalkylamines. Bioorg. Med. Chem., 15 Feb 2004, 12 (4), 825–831. 323 kB. http://dx.doi.org/10.1016/j.bmc.2003.10.027

Glennon, RA; Dukat, M; Grella, B; Hong, S; Costantino, L; Teitler, M; Smith, C; Egan, C; Davis, K; Mattson, MV. Binding of β-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors. Drug Alcohol Depend., 1 Aug 2000, 60 (2), 121–132. 276 kB. http://dx.doi.org/10.1016/S0376-8716(99)00148-9

Sy, W. Iodination of methoxyamphetamines with iodine and silver sulphate. Tetrahedron Lett., 24 Sep 1993, 34 (39), 6223–6224. 133 kB. http://dx.doi.org/10.1016/S0040-4039(00)73715-4

Glennon, RA; Titeler, M; McKenney, JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci., 17 Dec 1984, 35 (25), 2505–2511. 332 kB. http://dx.doi.org/10.1016/0024-3205(84)90436-3

Scorza, M; Carrau, C; Silveira, R; Zapata-Torres, G; Cassels, BK; Reyes-Parada, M. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives. Biochem. Pharmacol., 15 Dec 1997, 54 (12), 1361–1369. 697 kB. http://dx.doi.org/10.1016/S0006-2952(97)00405-X

McKenna, DJ; Mathis, CA; Shulgin, AT; Sargent, T; Saavedra, JM. Autoradiographic localization of binding sites for 125I-DOI, a new psychotomimetic radioligand, in the rat brain. Eur. J. Pharmacol., 1 Jan 1987, 137 (2–3), 289–290. 232 kB. http://dx.doi.org/10.1016/0014-2999(87)90239-1

Huang, X; Nichols, DE. 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur. J. Pharmacol., 1 Jan 1993, 238 (2–3), 291–296. 553 kB. http://dx.doi.org/10.1016/0014-2999(93)90859-G

2,5-IDNNA · IDNNA
DOI-NB
DOI-NB-NM
2,5-INCNMA
2,5-INCPMA
2,5-INNEA
2,5-IDMAPA
2,5-INDoA
2,5-INHeA
2,5-IDNA
2,5-IDMNiPrNMeA
2,5-INiPrA
DOI-NBOMe
DOI-NBMD
DOI-NBOH
DOI-Ac
2,5-INAA
2,5-INHA
2,5-INMeOEtA
2,5-INHeNMeA
2C-I
4C-I
ALEPH
ALEPH-2
ALEPH-4
ALEPH-6
ALEPH-7
2,5-DMA
DOAM
DOB
DOBU
DOC
DOEF
DOET
DOM
DON
DOPR
MEM
MPM
TMA-2
DOF
DOIB
DOTB
DOSB
DONH · DOA
DOAA
Hydroxy-DOPR
DOIP
MIPM
MBM
MAM
DOHE
DOBZ
DOCPM
ALEPH-8
ALEPH-5
ALEPH-16
ALEPH-21
DOTFM
2328
DOYN
DOCN
DOPh3
2325
2329
2330
DOVI
DOAC
DOCA
DOOH
DOCONHP
DOCOE
DOCEB
DOCEP
DOOC
DONMM
DOFM
DOHM
DOHP
DONO
DOEH
M(2OP)M
M(3OP)M
MBZM
ALEPH-19
ALEPH-S-amyl
ALEPH-S-PhEt
ALEPH sulfone
DOTFE
MTFEM
MDFEM
MFEM
DOBM
DOMCl
DOCET
DOTFPR
DOHSM
DOMSM
DOMOM
DONCO
DONCOE
DONCOTFM
DOCNM
1016
4-I-2-MA
IBOX
738
2CI-2ETO
3-I-2,6-DMA
ψ-DOI
2-I-3,5-DMA
5-I-2,4-DMA
6-I-2,3-DMA
2-I-4,5-DMA
2,5-IDNNA · IDNNA
DOI-NB
DOI-NB-NM
2,5-INCNMA
2,5-INCPMA
2,5-INNEA
2,5-IDMAPA
2,5-INDoA
2,5-INHeA
2,5-IDNA
2,5-IDMNiPrNMeA
2,5-INiPrA
DOI-NBOMe
DOI-NBMD
DOI-NBOH
DOI-Ac
2,5-INAA
2,5-INHA
2,5-INMeOEtA
2,5-INHeNMeA
2C-I
4C-I
ALEPH
ALEPH-2
ALEPH-4
ALEPH-6
ALEPH-7
2,5-DMA
DOAM
DOB
DOBU
DOC
DOEF
DOET
DOM
DON
DOPR
MEM
MPM
TMA-2
DOF
DOIB
DOTB
DOSB
DONH · DOA
DOAA
Hydroxy-DOPR
DOIP
MIPM
MBM
MAM
DOHE
DOBZ
DOCPM
ALEPH-8
ALEPH-5
ALEPH-16
ALEPH-21
DOTFM
2328
DOYN
DOCN
DOPh3
2325
2329
2330
DOVI
DOAC
DOCA
DOOH
DOCONHP
DOCOE
DOCEB
DOCEP
DOOC
DONMM
DOFM
DOHM
DOHP
DONO
DOEH
M(2OP)M
M(3OP)M
MBZM
ALEPH-19
ALEPH-S-amyl
ALEPH-S-PhEt
ALEPH sulfone
DOTFE
MTFEM
MDFEM
MFEM
DOBM
DOMCl
DOCET
DOTFPR
DOHSM
DOMSM
DOMOM
DONCO
DONCOE
DONCOTFM
DOCNM
1016
4-I-2-MA
IBOX
738
2CI-2ETO
3-I-2,6-DMA
ψ-DOI
2-I-3,5-DMA
5-I-2,4-DMA
6-I-2,3-DMA
2-I-4,5-DMA
24 June 2017 · Creative Commons BY-NC-SA ·